Click a topic below for an index of articles:





Financial or Socio-Economic Issues


Health Insurance



Institutional Issues

International Reports

Legal Concerns

Math Models or Methods to Predict Trends

Medical Issues

Our Sponsors

Occupational Concerns

Our Board

Religion and infectious diseases

State Governments

Stigma or Discrimination Issues

If you would like to submit an article to this website, email us at for a review of this paper


any words all words
Results per page:

“The only thing necessary for these diseases to the triumph is for good people and governments to do nothing.”


Madison Ave. Has Growing Role In the Business of Drug Research

Business/Financial Desk | November 22, 2002, Friday

Late Edition - Final , Section A , Page 1 , Column 1

ABSTRACT - Article on how Madison Avenue, whose television ads have helped turn some prescription drugs into billion-dollar products, is expanding role in drug development; lastest example is pain drug Bextra, sales of which soared sixty percent in three months after American Dental Assn journal published study showing it offered relief after dental surgery; federal regulators had rejected that conclusion six months earlier, leaving Pharmacia and Pfizer hard-pressed to market drug until more positive report came out; problem is that report came from Scirex, little-known research firm owned partly by Omnicom, one of world's largest ad companies; Omnicom, Interpublic and WPP have invested tens of millions of dollars in companies that perform clinical drug trials; critics like Dr Arnold S Relman and Dr Thomas Bodenheimer say it becomes impossible to separate marketing from science, while ad executives say intention is to direct research toward potential big sellers; federal law bars promotion of drugs before FDA aproval, but published research and medical education are exempt, and doctors may prescribe drugs for any purpose; Linda Logdberg, Lenard I Lesser and other industry critics also comment; photos; graph on sharp rise in drug-promotion spending (L) Dentists leafing through The Journal of the American Dental Association last May found a study concluding that a new drug called Bextra offered relief from one of their patients' worst nightmares -- the acute pain that follows dental surgery.


Federal regulators had rejected that conclusion only six months before, leaving Bextra's marketers, Pharmacia and Pfizer, hard pressed to sell it as an advance over Celebrex, their earlier entry in a crowded market for pain drugs.